FCGR3A and non-small cell lung carcinoma: Interestingly, this study will explore the combination of anti-HER2 CAR-T cells with cetuximab, taking advantage of the engineering of a non-cleavable CD16 into the T cell product to mediate antibody-dependent cytotoxicity (arm B) in patients with EGFR-expressing NSCLC, head and neck cancer, and colorectal cancer.